|1.||Avdoshin, V P: 3 articles (09/2012 - 03/2008)|
|2.||Andriukhin, M I: 3 articles (09/2012 - 03/2008)|
|3.||Singhasivanon, Pratap: 3 articles (01/2005 - 09/2003)|
|4.||Sithiprasasna, Ratana: 3 articles (01/2005 - 09/2003)|
|5.||Jones, James W: 3 articles (01/2005 - 09/2003)|
|6.||Teitelbaum, J: 2 articles (10/2014 - 01/2014)|
|7.||West, M: 2 articles (10/2014 - 01/2014)|
|8.||Zeiler, F A: 2 articles (10/2014 - 01/2014)|
|9.||Gillman, L M: 2 articles (10/2014 - 01/2014)|
|10.||Wagenlehner, Florian M E: 2 articles (01/2014 - 12/2011)|
03/01/1997 - "THAM uncompletely buffered acidosis but significantly improved contractility and relaxation. "
01/01/1977 - "Compared with 0.9 percent NaCl, both THAM and NaHCO3 were equally effective in correcting metabolic acidosis (p less than 0.05). "
12/10/1982 - "Substituting TRIS buffer for bicarbonate in the infusion also eliminated acidosis, but neither concentrations of 1 M or 5 M buffer prevented the stomachs from ulceration (6 out of 6 with 1 M buffer and 5 out of 6 with 5 M buffer). "
11/01/1963 - "[THERAPEUTIC TRIAL OF A NEW BUFFER AGENT (THAM) IN METABOLIC ACIDOSIS OF RENAL ORIGIN]."
11/01/2013 - "The effect of acidosis was investigated by metabolically buffering the hypercapnic acidosis with tromethamine. "
|2.||Urinary Tract Infections (Urinary Tract Infection)
12/01/2015 - "In the United States, an oral (tromethamine salt) formulation is used for uncomplicated urinary tract infections. "
02/01/2010 - "European, Japanese, South African and Brazilian usage practices are much broader, involving multiple formulations of FOM than the currently limited application of FOM in the United States, where uncomplicated urinary tract infection represents the only indication for FOM-tromethamine. "
01/01/2010 - "In two clinical studies, oral treatment with fosfomycin-trometamol was clinically effective against complicated or uncomplicated lower urinary tract infections caused by ESBL-producing E coli in, cumulatively, 75 (93.8%) of the 80 patients evaluated. "
05/01/2007 - "A single dose of fosfomycin trometamol is a safe and effective alternative in the treatment of asymptomatic urinary tract infections in the second trimester of pregnancy."
01/01/2005 - "Three hundred and seventeen non pregnant females, suffering of recurrent lower urinary tract infections (UTIs; at least three episodes in the preceding 12 months) were enrolled in a double blind, randomized placebo (PL) controlled, parallel group clinical study, addressed to evaluate the efficacy and safety of fosfomycin trometamol (CAS 78964-85-9, FT, Monuril) in the prevention of infectious recurrences of lower urinary tract. "
01/01/2010 - "For uncomplicated cystitis, only fosfomycin-trometamol is recommended as a first-line treatment, essentially because of its ecological advantages (resistance uncommon, no cross resistance with other antibiotic classes, specific class, sparing others). "
01/01/2008 - "Fosfomycin trometamol is a safe and effective alternative for the treatment of cystitis and asymptomatic UTI during pregnancy, and has become, in many countries, the first choice for treatment of any type of cystitis. "
01/01/2015 - "The antibiotic therapy of choice for an episode of acute uncomplicated cystitis is a single oral dose of fosfomycin trometamol. "
02/01/2014 - "The amount of antibiotic used when fosfomycin trometamol is taken every 10 days for 6 months is equivalent to treatment of 18 acute episodes of cystitis. "
02/01/2014 - "A single oral dose of fosfomycin trometamol is the antibiotic of choice for treating an episode of acute uncomplicated cystitis. "
03/01/2003 - "Irreversible ischemia of the hand after peripheral administration of tromethamol (THAM)."
01/01/1997 - "In HE staining, the reduction of ischemia, volume did not reach statistical significance (THAM: 49.1 +/- 9.9 mm3/9.6 +/- 1.8%; placebo: 66.3 +/- 14.5 mm3/13.1 +/- 2.8%). "
01/01/1997 - "In TTC staining, the ischemia volume--given in absolute values and percentage of the total left volume--was significantly reduced in the THAM group (THAM: 43.9 +/- 8.3 mm3/7.0 +/- 1.3%; placebo: 95.2 +/- 13.8 mm3/14.2 +/- 2.0%). "
01/01/2000 - "Ischemia-positive animals were selected and classified into the SM-20220- (0.5 mg/kg, i.p.) THAM- (2.0 ml/kg, i.v., 0.3M-THAM), combination of SM-20220 (0.5 mg/kg, i.p.) and THAM (2.0 ml/kg, i.v.), and vehicle- (0.9% saline, i.p.) treatment groups. "
08/01/1978 - "Addition of tris(hydroxymethyl)-aminomethane (Tris) (15 mM) to the perfusate at physiologic pH and PCO2 increased performance during ischemia to a greater extent and for a longer period than low PCO2 )15 mmHg), alkalotic (pH, 7.8) perfusate and a control sucrose perfusate. "
01/01/2014 - "Early Implementation of THAM for ICP Control: Therapeutic Hypothermia Avoidance and Reduction in Hypertonics/Hyperosmotics."
06/01/2002 - "The present findings indicate that mild hypothermia of 35 degrees C combined with THAM presents a potent cerebroprotective strategy. "
05/01/2000 - "Tris (hydroxymethyl)-aminomethane was administered in almost 49%, mild hypothermia in 37%, and hypertonic-hyperoncotic solutions in 28% of patients treated for an increase in intracranial pressure. "
08/01/1963 - "[THAM AND HYPOTHERMIA]."
06/01/2002 - "Mild hypothermia did not significantly reduce the brain water content beneath the hematoma (79.5 +/- 0.2%) compared to normothermia (80.2 +/- 0.2%), but mild hypothermia combined to THAM resulted in a significant reduction (78.7 +/- 0.0%; p < 0.01). "
|2.||Sodium Bicarbonate (Baking Soda)
|6.||Clavulanic Acid (Potassium Clavulanate)
|8.||Thioctic Acid (Lipoic Acid)
|10.||Anti-Bacterial Agents (Antibiotics)
|5.||Artificial Respiration (Mechanical Ventilation)